Akademik Veri Yönetim Sistemi
Inorganic Chemistry Communications, cilt.184, 2026 (SCI-Expanded, Scopus)
Cancer remains the most common disease, claiming the lives of hundreds of thousands of people worldwide. While cisplatin and platinum (II) derivatives continue to be widely used chemotherapeutic agents, extensive research has been conducted on ruthenium (Ru) arene complexes due to the undesirable side effects associated with the use of these metal drugs and the development of resistance in cancers. In this study, we aimed to analyze ruthenium arene complexes in different structures in cancer cell lines. Characterization of six bimetallic Ru complexes (Ru1a-3a, Ru1b-3b) was determined by nuclear magnetic resonance spectroscopy (1H and 13C NMR) and Fourier transform infrared spectroscopy. After that, the cellular properties of these complexes were analyzed on Du-145, LnCap, and PC-3 cell lines. Cytotoxic effects of ruthenium arene complexes were determined by MTT assay. CASP-3, CASP-8, CASP-9, BCL-2, BAX, P53, P21, P16, BCL-XL, CYCLIN D1, CDK4, CDK6, BID, PUMA, NOXA, AKT1, PTEN, MMP2 and MMP-9 gene mRNA expressions were evaluated by Real-time PCR. It was found that ruthenium arene complexes in prostate cancer cells suppressed migration and colony formation by using wound healing and colony formation assays, respectively. In conclusion, it is thought that ruthenium arene complexes indicate anticarcinogenesis activity by affecting cell cycle arrest, apoptosis, migration, and colony formation in prostate cancer cells.